Skip to main content
Premium Trial:

Request an Annual Quote

BC Platforms Teams With SAS on Analysis of Genomic, Other Patient Data

NEW YORK – BC Platforms said on Tuesday that it has partnered with analytics giant SAS Institute to provide life sciences and healthcare organizations with curated genomics and other patient data. The companies expect that the partnership will help them break down data silos and ultimately improve prediction of health outcomes.

Zurich-based BC Platforms and Cary, North Carolina-based SAS said that they already have many of the same clients in pharmaceutical development and healthcare delivery. The firms said they will "discover new ways to derive insights" from genomics and other patient data, such as imaging and blood chemistry.

"Big data is not close to reaching its full potential in health," Nino da Silva, deputy managing director for BC Platforms, said in a statement. "But through our partnership, which provides access to carefully curated patient data, including genomic data, we will deliver tangible results that will make a difference to drug development, healthcare provision, and patient outcomes."

Scott McClain, principal industry consultant at SAS, added that the partnership "ensures users get closer to the high-quality genomics and real-world data networks they need to make bold discoveries that drive progress."

The new collaboration adds to BC Platforms' other recent partnerships, including with Singapore Health Services, the African Institute of Everyone Genome, and Cure Duchenne.

The Scan

PLOS Papers on Crimean-Congo Hemorrhagic Fever in Russia, Avian Influenza in Australia, More

In PLOS this week: Researchers isolate CCHFV; avian influenza A virus patterns characterized; more.

Increasing Access to COVID-19 Technology

The US government has agreed to put licenses for 11 medical technologies developed at the NIH into a "patent pool" designed to help low- and middle-income countries access the tech.

Prime Acquisition Targets

A report in Stat posits that early-stage startup companies are the most likely targets in a coming surge of mergers and acquisitions in the biotech space.

Sarin Exposure, Genotypes, and Gulf War Syndrome

Soldiers with a certain genotype who were exposed to sarin gas were more likely to develop Gulf War Syndrome, a new study has found.